|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 107.00 SAR | +1.04% |
|
+9.18% | +12.63% |
| 03-09 | Tadawul All Share Index Tumbles as Triple-Digit Oil Weighs | MT |
| 03-09 | Nahdi Medical's FY25 Net Profit, Revenue Rise | MT |
Company Valuation: Nahdi Medical Company
Data adjusted to current consolidation scope
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 21,736 | 17,810 | 15,288 | 13,767 | 13,767 | - |
| Change | - | -18.06% | -14.16% | -9.95% | 0% | - |
| Enterprise Value (EV) 1 | 21,828 | 18,075 | 15,861 | 15,005 | 14,793 | 14,951 |
| Change | - | -17.19% | -12.25% | -5.4% | -1.41% | 1.07% |
| P/E ratio | 24.5x | 19.9x | 18.6x | 16.8x | 15.7x | 14.4x |
| PBR | 9.69x | 7.92x | 5.91x | 5.19x | 4.99x | 4.7x |
| PEG | 2.64x | 33.98x | -2.28x | -44.23x | 2.14x | 1.56x |
| Capitalization / Revenue | 2.52x | 2.04x | 1.62x | 1.21x | 1.24x | 1.15x |
| EV / Revenue | 2.53x | 2.07x | 1.68x | 1.48x | 1.33x | 1.25x |
| EV / EBITDA | 13.6x | 11.4x | 10.1x | 8.85x | 8.14x | 7.61x |
| EV / EBIT | 21.8x | 18.8x | 18.2x | 16.3x | 15x | 13.8x |
| EV / FCF | - | 18.4x | 14.3x | 25.3x | 17.6x | 17.7x |
| FCF Yield | - | 5.45% | 6.98% | 3.95% | 5.68% | 5.66% |
| Dividend per Share 2 | - | 5.5 | 5.5 | 5.421 | 5.684 | 6.127 |
| Rate of return | - | 4.01% | 4.68% | 5.12% | 5.37% | 5.79% |
| EPS 2 | 6.83 | 6.87 | 6.31 | 6.286 | 6.746 | 7.368 |
| Distribution rate | - | 80.1% | 87.2% | 86.2% | 84.3% | 83.2% |
| Net sales 1 | 8,616 | 8,714 | 9,446 | 10,210 | 11,093 | 11,941 |
| EBITDA 1 | 1,599 | 1,579 | 1,577 | 1,720 | 1,818 | 1,965 |
| EBIT 1 | 1,003 | 961 | 873.2 | 927 | 984.5 | 1,083 |
| Net income 1 | 887.8 | 892.6 | 820.7 | 831 | 877.5 | 972.4 |
| Net Debt 1 | 91.79 | 265.1 | 572.9 | 1,238 | 1,026 | 1,184 |
| Reference price 2 | 167.20 | 137.00 | 117.60 | 105.90 | 105.90 | 105.90 |
| Nbr of stocks (in thousands) | 130,000 | 130,000 | 130,000 | 130,000 | 130,000 | - |
| Announcement Date | 20/03/23 | 17/03/24 | 10/03/25 | 09/03/26 | - | - |
1SAR in Million2SAR
Estimates
P/E ratio, Detailed evolution
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
| 16.85x | 1.48x | 8.85x | 5.12% | 3.67B | ||
| 29.09x | 1.56x | 25.3x | -.--% | 21.09B | ||
| 31.37x | 1.79x | 26.37x | -.--% | 10.83B | ||
| 17.1x | 0.76x | 7.89x | 1.98% | 6.18B | ||
| 19.93x | 1.28x | 9.03x | 3.26% | 4.33B | ||
| 16.63x | 1.08x | 7.63x | 2.43% | 4.19B | ||
| 18.62x | 0.73x | 6.18x | 3.01% | 3.2B | ||
| 49.98x | - | - | - | 2.13B | ||
| 24.53x | 0.75x | 9.37x | 1.65% | 1.85B | ||
| Average | 24.90x | 1.18x | 12.58x | 2.18% | 6.39B | |
| Weighted average by Cap. | 25.89x | 1.38x | 18.22x | 1.23% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Equities
- 4164 Stock
- Valuation Nahdi Medical Company
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition
















